Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck Kgaa Spns/Adr (OP:MKKGY)

24.94 -0.82 (-3.18%)
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck Kgaa Spns/Adr

< Previous 1 2 Next >
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗
Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility program in 2026. 
Via Benzinga
Topics Government
News headline image
Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗
Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance, missed targets, and lost market share. 
Via Benzinga
News headline image
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
From Crown Bioscience
Via JCN Newswire
News headline image
Germany's Merck To Launch Semiconductor Base In China ↗
 
Via Benzinga
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition. 
Via Benzinga
Topics Intellectual Property
News headline image
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages. 
Via Benzinga
News headline image
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition ↗
Pfizer Inc (NYSE: PFE)  
Via Benzinga
News headline image
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
News headline image
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.  
Via Benzinga
News headline image
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗
Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported  
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
News headline image
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,  
Via Benzinga
News headline image
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗
 
Via Benzinga
News headline image
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗
 
Via Benzinga
News headline image
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗
 
Via Benzinga
News headline image
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗
 
Via Benzinga
News headline image
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗
 
Via Benzinga
News headline image
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗
 
Via Benzinga
News headline image
Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗
 
Via Benzinga
News headline image
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19 ↗
Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger 
Via Benzinga
News headline image
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug ↗
The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox. 
Via Benzinga
News headline image
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers ↗
 
Via Benzinga
News headline image
TSM Looks To Hire Over 8,000 People In 2022 ↗
Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial... 
Via Benzinga
News headline image
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing ↗
Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
News headline image
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact ↗
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... 
Via Benzinga
News headline image
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study ↗
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE... 
Via Benzinga
News headline image
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial ↗
Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.